RxDoctor Payments Data

Paula Pinell-Salles, MD

Cardiovascular Disease · Falls Church, VANPI 1396886396

Payments from drug & device makers

$923in general payments, 2019–2025

Across 50 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$226
  • E.r. Squibb & Sons, L.L.C.$118
  • AstraZeneca$91
  • Abbott$65
  • Amgen$55
  • Recor Medical Inc$46
  • plus $322 from 14 others

What the payments were for

  • Food & beverage$923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$923 in reported general payments places this provider in the 35th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$258,673
Medicare patients
1,737
Services billed
3,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$291,686
JardianceEmpagliflozin103$149,594
EntrestoSacubitril/Valsartan58$83,996
XareltoRivaroxaban37$57,767
Repatha SureclickEvolocumab35$43,032
FarxigaDapagliflozin Propanediol32$39,593
MultaqDronedarone Hcl11$25,659
VascepaIcosapent Ethyl14$13,977
Rosuvastatin Calcium284$5,577
Ezetimibe181$5,202
Ranolazine ErRanolazine30$4,072
Metoprolol Succinate274$3,300
Atorvastatin Calcium323$3,079
Valsartan58$2,612
Diltiazem 24hr Er (Cd)Diltiazem Hcl68$1,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$291,686204 claims
Boehringer IngelheimJardiance$26$149,594103 claims
NovartisEntresto$226$83,99658 claims
Johnson & JohnsonXarelto$29$57,76737 claims
AstraZenecaFarxiga$91$39,59332 claims
Sanofi-aventis U.S. LLCMultaq$20$25,65911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →